Induction of Th17 Lymphocytes and Treg Cells by Monocyte-Derived Dendritic Cells in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus

Lizbeth Estrada-Capetillo, Berenice Hernández-Castro, Adriana Monsiváis-Urenda, Crisol Álvarez-Quiroga, Esther Layseca-Espinosa, Carlos Abud-Mendoza, Lourdes Baranda, Ana Urzainqui, Francisco Sánchez-Madrid, and Roberto González-Amaro

1 Department of Immunology, Facultad de Medicina, UASLP, Avenue V. Carranza 2405, 78210 San Luis Potosí, SLP, Mexico
2 Regional Unit of Rheumatology and Osteoporosis, Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, SLP, Mexico
3 Servicio de Inmunología, Hospital de La Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria Princesa, Madrid, Mexico

Correspondence should be addressed to Roberto González-Amaro; rgonzale@uaslp.mx

Received 1 May 2013; Accepted 5 September 2013

Academic Editor: Jianying Zhang

Dendritic cells (DCs) have a key role in the regulation of immune response. We herein explored, in patients with inflammatory diseases, the role of monocyte-derived DCs (mo-DCs) on the generation of Th17 and T regulatory (Treg) lymphocytes. Peripheral blood was obtained from thirty-five patients with rheumatoid arthritis (RA), twelve with systemic lupus erythematosus (SLE), and twenty healthy subjects. Mo-DCs were generated under standard (IL-4/GM-CSF) or tolerogenic (IL-4/GM-CSF plus recombinant P-selectin or PD-1 or IL-10) conditions, and their ability to induce Th17 and Treg lymphocytes was tested. We detected that mo-DCs from patients with RA showed an enhanced release of IL-6 and IL-23 as well as an increased ability to induce Th17 cells. Although mo-DCs from SLE patients also released high levels of IL-6/IL-23, it did not show an increased ability to induce Th17 lymphocytes. In addition, mo-DCs, from patients with RA and SLE generated under the engagement of PSGL-1, showed a defective capability to induce Foxp3+ Treg cells. A similar phenomenon was observed in SLE, when DC’s cells were generated under PDL-1 engagement. Our data indicate that DCs from patients with rheumatic inflammatory disease show an aberrant function that may have an important role in the pathogenesis of these conditions.

1. Introduction

The defective regulation of the activation and proliferation of auto-reactive T cells that are not deleted in the thymus may result in different autoimmune disorders [1]. Initially, several inflammatory autoimmune diseases were considered to be entirely mediated by Thl lymphocytes, which mainly synthesize IL-2 and IFN-γ. However, in recent years, different studies have demonstrated that Th17 lymphocytes also play an important role in the pathogenesis of these conditions, including multiple sclerosis, psoriasis, inflammatory bowel disease, Hashimoto’s thyroiditis, and rheumatoid arthritis [2–8]. In addition, Th17 cells and Th17 cytokines are also involved in the pathogenesis of fibrotic autoimmune diseases as primary biliary cirrhosis (PBC) and systemic sclerosis (SSc) [9]. Th17 lymphocytes are a subset of CD4+ T cells characterized by the synthesis of IL-17A, IL-21, and IL-22, and the expression of IL-23R and CCR6 receptors [10]. Interleukin IL-17A is a proinflammatory cytokine that induces the synthesis of TNF-α, IL-1β, IL-6, IL-8, GM-CSF, different metalloproteinases (MMP-1, -3, -9), chemokines (CCL2, 3), and PGE2 by different cell types, including fibroblasts, epithelial and endothelial cells, keratinocytes, osteoblasts, and monocyte/macrophages [11–13]. In addition, in patients with...
rheumatoid arthritis (RA), IL-17 is involved in the destruction of the extracellular matrix and juxtaarticular bone resorption, through the induction of synthesis of RANKL and matrix metalloproteases [14, 15].

The differentiation of human Th17 lymphocytes is induced by the combined action of different cytokines, including IL-1β, IL-6, and IL-23 [16], whereas IL-21 promotes the survival and expansion of these cells [17, 18]. In addition, TGF-β seems to also participate in the differentiation of Th17 cells, which may have a conventional or a regulatory phenotype [19, 20].

Dendritic cells (DCs) are professional antigen presenting cells that play a key role in the induction and regulation of T cell mediated responses [21]. Two main DC subsets have been characterized in humans, myeloid, and plasmacytoid DCs (mDCs, CD11c+, pDCs, and CD11c–) [22]. In addition, when monocytes are cultured in the presence of GM-CSF and IL-4, differentiate into a subset of mDCs (monocyte derived DCs or MDDCs or mo-DCs) [23]. DCs express a wide repertoire of membrane receptors, including pattern recognition receptors (PRRs), which upon engagement by their ligands (DAMPs and PAMPs) induce their terminal differentiation and activation [21]. It has been described that a subfamily of PRRs (C-type lectin receptors or CLRs) induce the activation of Syk and CARD9 and preferentially induce the polarization of naïve Th0 lymphocytes towards Th17 cells [24–26]. On the other hand, it has also been described that tolerogenic DCs are able to inhibit the differentiation of naïve Th0 lymphocytes, suppressing thus the generation of T cell mediated immune responses [27]. Conversely, tolerogenic DCs are able to induce the generation of T regulatory (Treg) lymphocytes [28]. In this regard, it has been described that different membrane receptors (e.g., PSGL-1 and PDL-1) as well as cytokines (e.g., IL-10) are able to induce the generation of tolerogenic DCs [29, 30].

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by chronic synovial inflammation, which results in cartilage and bone damage, leading to joint destruction. Different cell types and their mediators are involved in the tissue destructive inflammation seen in this condition, including Th17 lymphocytes [31]. In this regard, mice deficient in IL-17 show a decreased induction of collagen induced arthritis (CIA) [32]. Accordingly, in this animal model of RA, the neutralization of IL-17 reduces joint inflammation, cartilage destruction, and bone erosion [33]. In humans, elevated concentrations of IL-17 have been found in synovial fluid and in peripheral blood of RA patients as well as a high proportion of Th17 lymphocytes in their peripheral blood [34]. In fact, different data indicate that the inflamed rheumatoid synovium is a tissue niche that greatly favors the generation of Th17 cells [35]. Recently, Vaknin-Dembinsky et al. showed that mo-DCs from patients with multiple sclerosis show an enhanced synthesis of IL-23 as well as an increased ability to induce the in vitro differentiation of Th17 lymphocytes [36]. However, the precise role of IL-23 and DCs on the induction of Th17 cells in patients with RA has not been fully characterized.

SLE is an autoimmune, systemic, inflammatory condition with many different immunologic aberrations, including an enhanced synthesis of IL-10 and type I interferon, a diminished function of natural Treg lymphocytes, and an aberrant phenotype and function of DCs [37]. As in the case of RA, different reports indicate that Th17 lymphocytes are involved in the pathogenesis of SLE, including lupus nephritis [38, 39]. We have herein studied the role of immunogenic and tolerogenic DCs on the in vitro induction of Th17 cells and Treg lymphocytes in patients with RA and SLE. We detected that mo-DCs from patients with RA show an enhanced release of IL-6/IL-23 and an increased capability to induce Th17 cells. On the other hand, tolerogenic mo-DCs from patients with RA and SLE showed a defective capability to induce the generation of Foxp3+ Treg cells. These results further support the important role of DCs in the pathogenesis of autoimmune diseases, and indicate that it is interesting to comparatively evaluate the generation of effector and regulatory lymphocytes in these conditions [9].

2. Materials and Methods

2.1. Patients. Thirty-five female patients with RA, with a mean age of 42.3 years, diagnosed according to the criteria of the American College of Rheumatology (ACR) [40] were included in the study. Fifteen patients were untreated at the time of their inclusion in the study, and their mean Disease Activity Score 28 (DAS28) was 4.09. The remaining patients (with a mean DAS28 of 3.45) were under therapy with disease-modifying antirheumatic drugs (DMARDs), receiving mainly low-dose methotrexate (14.9 ± 3.8 mg/week) and sulfasalazine (1.4 ± 0.7 g/day). Twelve female patients with SLE, according to the classification criteria of the American College of Rheumatology [41], were also studied. Their mean age was 33.1 years (range: 16–39), and the mean duration of disease was 19 months. All these patients were not receiving immunosuppressive drugs at the time of the study, and eight of them had active disease, with a MEX-SLEDAI Score >3.0 [42]. Three patients were under therapy with low doses of prednisone (10–20 mg/day), and two were receiving hydroxychloroquine (200 mg/day). No patients with renal failure were included. No patients under therapy with biological agents were included in the study. Twenty female healthy individuals with a mean age 35.5 years were included as controls. This study was approved by the local University Ethics Committee and all subjects signed an informed consent.

2.2. Cells. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized venous blood by Ficoll-Hypaque density gradient centrifugation (Sigma-Aldrich, St. Louis, MO). Monocytes and CD4+ T cells were positively isolated from PBMC by using MicroBeads (Miltenyi Biotec) coupled to mAbs, according to manufacturer’s instructions. The purity of the isolated cells was verified by flow cytometry analysis and was always greater than 95%. After CD4+ T cells isolation, cells were incubated in complete RPMI culture medium with 2% of fetal calf serum (FCS) until they were used in coculture assays.
2.3. Generation of Monocyte-Derived Dendritic Cells (mo-DC). Monocytes (1 × 10^6/mL) were plated in RPMI-1640 culture medium supplemented with 10% FCS, 2.0 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin (Gibco BRL, Grand Island, NY), 1% sodium pyruvate (Gibco), 1% nonessential amino acids (Hyclone Laboratories, South Logan, UT), and 50 mM 2-mercaptoethanol (Gibco) in the presence of 200 ng/mL rhGM-CSF and 15 ng/mL rhIL-4 (eBiosciences) at 37°C and 5% of CO₂. Cells were fed on days 2 and 4 by changing one half of the medium and keeping the same concentration of IL-4 and GM-CSF. At day 6, DCs were induced to mature by adding 200 ng/mL of LPS (Sigma-Aldrich). Forty-eight hours after stimulation, supernatants were collected for cytokine measurement. In the case of the induction of tolerogenic dendritic cells, the differentiation of monocytes was carried out in 24-well tissue culture plates previously coated with recombinant human P-selectin (10 μg/mL) or PDI (2.5 μg/mL) (BioLegend, San Diego, CA) by overnight incubation at 4°C. In other set of experiments, monocytes were induced to differentiate in the presence of IL-10 (40 ng/mL, Biolegend).

2.4. Lymphocyte-DC CoCultures and Induction of Th17 and Treg Differentiation. For the induction of differentiation of Th17 cells, mature mo-DC and autologous CD4⁺ T cells were cocultured in 24-well plates at 1:10 ratio in complete Iscove's modified Dulbecco medium (IMDM, Gibco BRL). Plates were previously coated with 10 μg/mL anti-CD3 (eBiosciences) and anti-CD28 (Immunotech) mAbs, and Th17 differentiation was induced by adding rhIL-23 (10 ng/mL, R&D systems, Minneapolis, MN), IL-6 (50 ng/mL), IL-1β (10 ng/mL), IL-21 (50 ng/mL), TNF-α (10 ng/mL, all from eBiosciences), and anti-IL-4 and anti-IFN-γ mAbs (5 μg/mL, BioLegend). Under such conditions, cells were cultured during 5 days at 37°C and 5% of CO₂, and then the percent of Th1 and Th17 cells was determined by flow cytometry. In the case of the induction of Th1/Th17 cells, no anti-IFN-γ antibody was added. For induction of Treg cell differentiation, DCs generated in the presence of tolerogenic stimuli (IL-10, PDI, P-selectin) were cocultured with autologous CD4⁺ T cells for five days, and then cells were immunostained for CD4, CD25, and Foxp3, and they were analyzed by flow cytometry.

2.5. Flow Cytometry Analysis. Myeloid and plasmacytoid dendritic cells were analyzed by using a mixture of mAbs specific for lineage markers combined with HLA-DR, CD11c, BDCA-2, and BDCA-4 mAbs. The following antibodies were used: FITC labeled anti-CD3, anti-CD14, anti-CD16, anti-CD19, and anti-CD56 (eBiosciences); HLA-DR-APC-Cy7, CD11c-PerCP, PE, CD3-PE-Cy7, BDCA-2-APC and BDCA-4-APC (Miltenyi Biotec). Cells were analyzed in a FACSaria II flow cytometer (Becton Dickinson, San José, CA) using the FACS Diva software.

For intracellular cytokine analysis, cells were treated for 5 hours with PMA plus ionomycin (50 ng/mL, and 1 μg/mL, resp., Sigma-Aldrich) and with Brefeldin A (1 μg/mL, Cytofix/Cytoperm kit, eBioscience) for the last 2 hours. Then, cells were stained for the indicated cell surface markers, fixed, permeabilized (Cytofix/Cytoperm kit, eBiosciences), and labeled for IL17 (anti-IL-17-PE, R&D Systems) and IFN-γ (anti-IFN-γ-FITC, eBiosciences) for 30 min at 4°C. Cells were analyzed in a FACSCalibur flow cytometer (Becton-Dickinson) using the CellQuest Pro software.

Cell surface markers of mo-DCs were analyzed with mAbs directed against CD83, CD86, PSGL-1, PDL-1 (eBiosciences), and HLA-DR (BD Pharmingen). In all analyzes, Fcγ receptors were blocked (FcyR binding inhibitor, eBiosciences) before immunostaining.

2.6. Cytokine Quantification. Levels of IL-23, IL-1β, IL-6, IL-22, IL-17A, and IFN-γ were quantified in cell-free supernatants using Human ELISA kits (eBiosciences and PEPRO-TECH) according to manufacturer's instructions. All determinations were performed by duplicate, and plates were analyzed by using a Multiskan ELISA reader.

2.7. Statistical Analyses. Differences between two groups were determined using the Student's t test or Mann-Whitney U test. One and two way analysis of variance with the proper post hoc analysis was performed when necessary. Data were analyzed using the GraphPad Prism software (GraphPad, San Diego, CA).

3. Results

3.1. Peripheral Blood DC Subsets and mo-DCs in Patients with RA and SLE. We first analyzed the levels of DCs subsets in the peripheral blood from patients and controls. As shown in Figure 1(a), patients with RA and SLE showed an enhanced proportion of CD11c⁺ BDCA-2⁺ myeloid DCs (P < 0.05 in both cases). Furthermore, patients with SLE exhibited higher levels of CD11c⁺ BDCA-4⁺ plasmacytoid DCs compared to both healthy controls and patients with RA (P < 0.05 in both cases). However, no apparent association between disease activity or immunosuppressive therapy and DCs levels was detected in patients with SLE or RA (data not shown). As shown in Figure 1(b), the peripheral blood myeloid DCs from patients with RA and SLE exhibited an enhanced expression of the regulatory receptors PSGL-1 and PDL-1 (P < 0.05 in all cases, compared to healthy controls). In the case of plasmacytoid DCs, although the expression of PDL-1 tended to be higher in patients with RA and SLE, no significant differences were observed compared to controls (P > 0.05 in both cases, Figure 1(b)). In contrast, the expression of PSGL-1 was significantly higher in plasmacytoid DCs from patients with RA and SLE compared to cells from healthy subjects (P < 0.05 in both cases, Figure 1(b)).

We then generated in vitro mo-DCs under standard conditions with IL4/GM-CSF. As shown in Figure 1(c), and as we have previously reported [43], in the case of SLE, these myeloid DCs exhibited a diminished density of expressions of CD80, CD86, and HLA-DR (measured as their MFI). In contrast, the phenotype of mo-DCs was similar in patients with RA and healthy controls. In addition, a similar pattern of PSGL-1 and PDL-1 expression was observed in mo-DCs.
from the patients included in this study (data not shown). On the other hand, when different cytokines were measured in the cell culture supernatants of mo-DCs, we observed an enhanced release of IL-6 and IL-23 by cells from patients with RA and SLE, compared to healthy individuals (P < 0.05 in all cases, Figure 1(d)). In contrast, similar concentrations of IL-1β were detected in the cell culture supernatants from patients and controls (P > 0.05, Figure 1(d)).

3.2. Effect of DCs on the In Vitro Differentiation of Th17 Lymphocytes. We first analyzed by flow cytometry the proportion of Th17 cells in the PBMC of healthy controls and patients. As shown in Figure 2, patients with RA and SLE showed enhanced levels of CD4+ IL-17A+ lymphocytes compared to controls (P < 0.05 in both cases). In addition, the percentage of Th1/Th17 lymphocytes (defined as CD4+ IL-17A+ IFN-γ+) was also higher in patients with RA or SLE.

Figure 1: Peripheral blood DCs subsets and mo-DCs in patients with RA and SLE. (a) Myeloid and plasmacytoid DCs levels were determined in freshly isolated peripheral blood mononuclear cells by multiparametric flow cytometry, as stated in materials and methods. Data correspond to the percent of CD11c+ BDCA-2+ nonlineage cells (myeloid DCs), and CD11c− BDCA-4+ nonlineage cells (plasmacytoid DCs). (b) The expression of the regulatory receptors PSGL-1 and PD-1 by myeloid and plasmacytoid DCs was analyzed by multiparametric flow cytometry in blood samples from patients with RA and SLE, as stated in materials and methods. (c) mo-DCs were generated in vitro by culturing peripheral blood monocytes in the presence of IL-4 and GM-CSF, and their maturation was induced by LPS. Then, cells were immunostained for the indicated molecules, and analyzed by flow cytometry. Data correspond to the percent of positive cells (left panel), and mean fluorescence intensity (MFI, right panel) in cells from representative patients with RA and SLE, and a healthy control. (d) IL-1β, IL-6 and IL-23 were quantified in the cell culture supernatants of mo-DCs incubated in the presence of LPS. Median and interquartile range are shown in (a) and (d) and the arithmetic mean and SD in (c). *P < 0.05. In all panels, white boxes correspond to controls, grey light boxes to patients with RA, and grey dark boxes to SLE patients.
compared to healthy subjects \( (P < 0.05 \text{ in both cases}) \). Similar results were observed in the case of CD4\(^{-}\) IL-17+ lymphocytes \( (P < 0.05 \text{ in both cases, data not shown}) \). Interestingly, patients with RA under therapy with DMARDs showed significantly lower levels of Th17 cells compared to untreated patients \( (P < 0.05, \text{ data not shown}) \). However, no significant correlation between disease activity (DAS28 score) and Th17 levels was detected in these patients \( (r = 0.17, P > 0.05, \text{ data not shown}) \). In contrast, a significant correlation between SLEDAI score and Th17 percentages was observed in patients with SLE \( (r = 0.39, P < 0.05, \text{ data not shown}) \).

When the mo-DCs from patients with RA were cocultured with autologous CD4\(^{+}\) T cells, we detected an enhanced generation of Th17 (CD4\(^{+}\) IL-17A\(^{+}\)) lymphocytes \( (P < 0.05 \text{ compared to controls, Figure 3(a)}) \). As expected, this phenomenon was enhanced when cells were cultured under Th17 polarizing conditions (addition of IL-1, IL-6, IL-21, and TNF-\(\alpha\), with blockade of IL-4 and IFN-\(\gamma\), Figure 3(a)). However, although the addition of IL-23 alone tended to have a similar effect, no significant differences between RA and controls were reached \( (P > 0.05, \text{ Figure 3(a)}) \). Furthermore, similar levels of Th17 induction were observed in cells from patients with SLE and controls, in the different conditions tested \( (P > 0.05 \text{ in all cases, Figure 3(a)}) \). Finally, although cell cocultures from patients with RA and SLE tended to show an increased generation of Th1/Th17 lymphocytes (CD4\(^{+}\) IL-17A\(^{+}\) IFN-\(\gamma\)\(^{+}\)), no significant differences were observed when compared to cells from healthy controls \( (P > 0.05 \text{ in all cases, Figure 3(b)}) \). In agreement with the above results, we observed a significant enhanced release of Th17 cytokines (IL-17A and IL-22) in the mo-DC/T lymphocyte cocultures from patients with RA (Figure 4).

3.3. Effect of Tolerogenic DCs on the Induction of Treg Lymphocytes. An additional analysis of the functional status of mo-DCs in SLE and RA was performed, by measuring their capability to induce Treg lymphocytes. When mo-DCs were generated under standard conditions (IL-4/GM-CSF), those derived from SLE patients showed a diminished capability to induce the generation of autologous CD4\(^{+}\) CD25\(^{+}\) Foxp3\(^{+}\) Treg cells \( (P < 0.05 \text{ compared to controls, Figure 5}) \). Interestingly, when mo-DCs were generated under the engagement of the tolerogenic receptor PSGL-1 (by the addition of exogenous P-selectin), a diminished capability to promote the generation of Treg lymphocytes was observed in patients with RA and SLE \( (P < 0.05 \text{ compared to controls, Figure 5}) \). A similar phenomenon was observed in the case of mo-DCs from patients with SLE, when they were generated in the presence of recombinant PD-1 \( (P < 0.05 \text{ compared to controls, Figure 5}) \). Although mo-DCs from patients with RA generated under PDL-1 engagement tended to show a diminished ability to induce Treg cells, no significant difference was reached in this case \( (P > 0.05, \text{ Figure 5}) \).

4. Discussion

Different data indicate that in the complex pathogenesis of RA and SLE, DCs as well as Th17 and Treg lymphocytes have
an important role [8, 31, 36]. In this work, we first analyzed the levels of Th17 lymphocytes and the two main subsets of peripheral blood DCs in samples from these patients and healthy controls. In agreement with previous reports [12, 44, 45], and as has been observed in other conditions such as PBC or SSc [9], we detected enhanced levels of Th17 lymphocytes in the peripheral blood from patients with RA and SLE. However, it is of interest that other authors have not observed increased numbers of these T helper cells in patients with RA [43]. It is feasible that these apparent contradictory results could be due to differences in the therapy, time of disease evolution, level of disease activity or genetic background of patients. In this regard, we have detected that those patients under therapy with DMARDs exhibit lower percentages of Th17 cells than those in untreated patients. In addition, we found a significant association between disease activity and Th17 cell levels in patients with SLE. However, in patients with RA this correlation was not detected. All these data indicate that it would be interesting to perform a longitudinal study of Th17 cell levels in a cohort of patients with RA and SLE.

In order to further explore the role of DCs in the induction of Th17 lymphocytes in patients with RA and SLE, we performed in vitro experiments with mo-DCs. In this regard, it is worth mentioning that although this type of DCs is not detected in the peripheral blood of healthy subjects, different evidences indicate that this subset of antigen presenting cells is generated in vivo [46]. Our results indicate that the mo-DCs from patients with RA have an increased capability to induce the in vitro differentiation of Th17 lymphocytes as well as an enhanced potential to release cytokines that allow the generation of these cells. These data further support the important role of DCs in the pathogenesis of RA and indicate that this functional feature is preserved during their in vitro generation from peripheral blood monocytes. In addition, our results also support that the inflamed rheumatoid synovium is a privileged site for the generation of Th17 cells [35]. Since this enhanced capability of mo-DCs to induce Th17 lymphocytes was not observed in patients with SLE, our data indicate that, under our experimental conditions, the overproduction of IL6/IL-21/IL-23 by DCs is not enough to increase the differentiation of Th17 lymphocytes. In this regard, it is of interest that we have corroborated [47] that mo-DCs from patients with SLE show a defective expression of HLA-DR and the costimulatory molecule CD86. Thus,
Figure 5: Induction of Treg lymphocytes by mo-DCs from patients with RA and SLE. Monocyte derived DCs generated under tolerizing conditions (PDL-1, PSGL-1 engagement, or IL-10 addition) or not, were cocultured with autologous CD4+ lymphocytes for five days. Then, the percent of CD4+ CD25+ Foxp3+ lymphocytes was determined by flow cytometry. Data correspond to the median and interquartile range of the percent of positive cells. ∗P < 0.05.

5. Conclusions

Our findings strongly suggest that mo-DCs may significantly contribute to the enhanced generation of Th17 lymphocytes, and the diminished number and activity of Treg cells observed in patients with RA and SLE. Thus, the possible functional role of this subset of DCs in vivo, in the pathogenesis of autoimmune inflammatory conditions, is an interesting point to be further explored.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Lizbeth Estrada-Capetillo and Berenice Hernández-Castro contributed equally to this work.

Acknowledgment

This work was supported by a grant from FONCICYT (95395, CONACYT-European Union, México) to RG-A and FS-M.

References

[1] A. O’Garra and P. Vieira, “Regulatory T cells and mechanisms of immune system control,” *Nature Medicine*, vol. 10, pp. 801–805, 2004.
[2] C. L. Langrish, Y. Chen, W. M. Blumenschein et al., “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation,” *Journal of Experimental Medicine*, vol. 201, no. 2, pp. 233–240, 2005.
[3] Y. Komiyama, S. Nakae, T. Matsuki et al., “IL-17 plays an important role in the development of experimental autoimmune
encephalomyelitis," *Journal of Immunology*, vol. 177, no. 1, pp. 566–573, 2006.

[4] C. Sutton, C. Brereton, B. Keogh, K. H. G. Mills, and E. C. Lavelle, "A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis," *Journal of Experimental Medicine*, vol. 203, no. 7, pp. 1685–1691, 2006.

[5] N. J. Wilson, K. Boniface, J. R. Chan et al., "Development, cytokine profile and function of human interleukin 17-producing helper T cells," *Nature Immunology*, vol. 8, no. 9, pp. 950–957, 2007.

[6] J. Seiderer, I. Elben, J. Diegelmann et al., "Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD," *Inflammatory Bowel Diseases*, vol. 14, no. 4, pp. 437–445, 2008.

[7] N. Figueroa-Vega, M. Alfonso-Pérez, I. Benedicto, F. Sánchez-Madrid, R. González-Amaro, and M. Marazuela, "Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis," *Journal of Endocrinology and Metabolism*, vol. 95, no. 2, pp. 953–962, 2010.

[8] S. Sarkar, L. A. Cooney, and D. A. Fox, "The role of Th1 helper type 17 cells in inflammatory arthritis," *Clinical and Experimental Immunology*, vol. 159, no. 3, pp. 225–237, 2010.

[9] D. Fenoglio, F. Bernuzzi, F. Battaglia et al., "Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases," *Autoimmunity Reviews*, vol. 12, no. 2, pp. 300–304, 2012.

[10] F. Annunziato, L. Cosmi, F. Liotta, E. Maggi, and S. Romagnani, "The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation," *International Immunology*, vol. 20, no. 11, pp. 1361–1368, 2008.

[11] S. Kotake, N. Udagawa, N. Takahashi et al., "IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis," *Journal of Clinical Investigation*, vol. 103, no. 9, pp. 1345–1352, 1999.

[12] H. Shen, J. C. Goodall, and J. S. Hill Gaston, "Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis," *Arthritis and Rheumatism*, vol. 60, no. 6, pp. 1647–1656, 2009.

[13] D. V. Jovanovic, J. A. Di Battista, J. Martel-Pelletier et al., "IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages," *Journal of Immunology*, vol. 160, no. 7, pp. 3513–3521, 1998.

[14] E. Lubberts, M. Koenders, and W. B. van den Berg, "The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models," *Arthritis Research and Therapy*, vol. 7, no. 1, pp. 29–37, 2005.

[15] R. L. van Bezoijen, L. van der Wee-Pals, S. E. Papapoulos, and C. W. G. M. Löwik, "Interleukin 17 synergises with tumour necrosis factor α to induce cartilage destruction in vitro," *Annals of the Rheumatic Diseases*, vol. 61, no. 10, pp. 870–876, 2002.

[16] M. J. McGeachy, Y. Chen, C. M. Tato et al., "The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo," *Nature Immunology*, vol. 10, no. 3, pp. 314–324, 2009.

[17] N. J. Wilson, K. Boniface, J. R. Chan et al., "Development, cytokine profile and function of human interleukin 17-producing helper T cells," *Nature Immunology*, vol. 8, no. 9, pp. 950–957, 2007.

[18] D. Yen, J. Cheung, H. Scheeren et al., "IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6," *Journal of Clinical Investigation*, vol. 116, no. 5, pp. 1310–1316, 2006.

[19] E. Volpe, N. Servant, R. Zollinger et al., "A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses," *Nature Immunology*, vol. 9, no. 6, pp. 650–657, 2008.

[20] K. Ghoreschi, A. Laurence, X. Yang et al., "Generation of pathogenic TH17 cells in the absence of TGF-β 2 signalling," *Nature*, vol. 467, no. 7318, pp. 967–971, 2010.

[21] J. Banchereau and R. M. Steinman, "Dendritic cells and the control of immunity," *Nature*, vol. 392, no. 6673, pp. 245–252, 1998.

[22] N. Kadowaki, "Dendritic cells—a conductor of T cell differentiation," *Allergy International*, vol. 56, no. 3, pp. 193–199, 2007.

[23] A. Iwasaki and R. Medzhitov, "Regulation of adaptive immunity by the innate immune system," *Science*, vol. 327, no. 5963, pp. 291–295, 2010.

[24] S. LeibundGut-Landmann, O. Groff, M. J. Robinson et al., "Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17," *Nature Immunology*, vol. 8, no. 6, pp. 630–638, 2007.

[25] A. J. van Beelen, Z. Zelnikova, E. W. Taanman-Kueter et al., "Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells," *Immunity*, vol. 27, no. 4, pp. 660–669, 2007.

[26] M. Veldhoen, R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger, "TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells," *Immunity*, vol. 24, no. 2, pp. 179–189, 2006.

[27] R. M. Steinman, S. Turley, I. Mellman, and K. Inaba, "The induction of tolerance by dendritic cells that have captured apoptotic cells," *Journal of Experimental Medicine*, vol. 191, no. 3, pp. 411–416, 2000.

[28] H. Jonuleit, E. Schmitt, K. Steinbrink, and A. H. Enk, "Dendritic cells as a tool to induce anergic and regulatory T cells," *Trends in Immunology*, vol. 22, no. 7, pp. 394–400, 2001.

[29] H. Kuipers, F. Muskens, M. Willart et al., "Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ cell activation," *European Journal of Immunology*, vol. 36, no. 9, pp. 2472–2482, 2006.

[30] A. Urzainqui, G. M. Del Hoyo, A. Lamana et al., "Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells," *Journal of Immunology*, vol. 179, no. 11, pp. 7457–7465, 2007.

[31] M. Feldmann, F. M. Brennan, and R. N. Maini, "Rheumatoid arthritis," *Cell*, vol. 85, no. 3, pp. 307–310, 1996.

[32] S. Nakae, A. Nambu, K. Sudo, and Y. Iwakura, "Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice," *Journal of Immunology*, vol. 171, no. 11, pp. 6173–6177, 2003.

[33] E. Lubberts, M. I. Koenders, B. Oppers-Walogen et al., "Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion," *Arthritis and Rheumatism*, vol. 50, no. 2, pp. 650–659, 2004.

[34] M. Chabaud, J. M. Durand, N. Buchs et al., "Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium," *Arthritis and Rheumatism*, vol. 42, no. 5, pp. 963–970, 1999.
[35] W. Dong and P. Zhu, “Functional niche of inflamed synovium for Th17-cell expansion and activation in rheumatoid arthritis: implication to clinical therapeutics,” *Autoimmunity Reviews*, vol. 11, no. 12, pp. 844–851, 2012.

[36] A. Vaknin-Dembinsky, K. Balashov, and H. L. Weiner, “IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production,” *Journal of Immunology*, vol. 176, no. 12, pp. 7768–7774, 2006.

[37] G. S. Dean, J. Tyrrell-Price, E. Crawley, and D. A. Isenberg, “Cytokines and systemic lupus erythematosus,” *Annals of the Rheumatic Diseases*, vol. 59, no. 4, pp. 243–251, 2000.

[38] A. Ambrosi, A. Espinosa, and M. Wahren-Herlenius, “IL-17: a new actor in IFN-driven systemic autoimmune diseases,” *European Journal of Immunology*, vol. 42, no. 9, pp. 2274–3384, 2012.

[39] P. Pisitkun, H. L. Ha, H. Wang et al., “Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis,” *Immunity*, vol. 37, no. 6, pp. 1104–1115, 2012.

[40] F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis,” *Arthritis and Rheumatism*, vol. 31, no. 3, pp. 315–324, 1988.

[41] E. M. Tan, A. S. Cohen, J. F. Fries et al., “The 1982 revised criteria for the classification of systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 25, no. 11, pp. 1271–1277, 1982.

[42] A. G. Uribe, L. M. Vilá, G. McGwin Jr., M. L. Sanchez, J. D. Revelle, and G. S. Alarcón, “The systemic lupus activity measure-revised, the Mexican systemic lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus,” *Journal of Rheumatology*, vol. 31, no. 10, pp. 1934–1940, 2004.

[43] I. Arroyo-Villa, M. B. Bautista-Caro, A. Salsa et al., “Frequency of Th17 CD4+T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivity,” *PLoS One*, vol. 7, no. 8, Article ID e42189, 2012.

[44] N. E. Aerts, K. J. de knop, J. Leysen et al., “Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migrationassociated chemokine receptor expression,” *Rheumatology*, vol. 49, no. 12, Article ID keq224, pp. 2264–2272, 2010.

[45] K. Shah, W. W. Lee, S. H. Lee et al., “Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus,” *Arthritis Research and Therapy*, vol. 12, no. 2, article R53, 2010.

[46] F. Santiago-Schwarz, P. Anand, S. Liu, and S. E. Carsons, “Dendritic cells (DCs) in rheumatoid arthritis (RA): progenitor cells and soluble factors contained in RA synovial fluid yield a subset of myeloid DCs that preferentially activate Th1 inflammatory-type responses,” *Journal of Immunology*, vol. 167, no. 3, pp. 1758–1768, 2001.

[47] N. Figueroa-Vega, G. Galindo-Rodriguez, S. Bajaña et al., “Phenotypic analysis of IL-10-treated, monocyte-derived dendritic cells in patients with systemic lupus erythematosus,” *Scandinavian Journal of Immunology*, vol. 64, no. 6, pp. 668–676, 2006.

[48] M. C. Lebre, S. L. Jongbloed, S. W. Tas, T. J. J. Smeets, I. B. Mclnnes, and P. P. Tak, “Rheumatoid arthritis synovium contains two subsets of CD83+ DC-LAMP+ dendritic cells with distinct cytokine profiles,” *The American Journal of Pathology*, vol. 172, no. 4, pp. 940–950, 2008.

[49] B. Alvarado-Sánchez, B. Hernández-Castro, D. Portales-Pérez et al., “Regulatory T cells in patients with systemic lupus erythematosus,” *Journal of Autoimmunity*, vol. 27, no. 2, pp. 110–118, 2006.

[50] H. Y. Lee, Y. K. Hong, H. J. Yun, Y. M. Kim, J. R. Kim, and W. H. Yoo, “Altered frequency and migration capacity of CD4+ CD25+ regulatory T cells in systemic lupus erythematosus,” *Rheumatology*, vol. 47, no. 6, pp. 789–794, 2008.

[51] J. A. G. van Roon, S. A. Y. Hartgring, K. M. G. van der Wurff-Jacobs, J. W. J. Bijlisma, and F. P. J. G. Lefeber, “Numbers of CD25+Foxp3+ T cells that lack the IL-7 receptor are increased intra-articularly and have impaired suppressive function in RA patients,” *Rheumatology*, vol. 49, no. 11, Article ID keq237, pp. 2084–2089, 2010.

[52] J. J. Cush, J. B. Splawski, R. Thomas et al., “Elevated interleukin-10 levels in patients with rheumatoid arthritis,” *Arthritis and Rheumatism*, vol. 38, no. 1, pp. 96–104, 1995.